Executive exit at Revium Rx (RVRC) as COO, President and director Inna Martin resigns

(High)

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Revium Rx. reported that Ms. Inna Martin has resigned, effective immediately, from her roles as Director, Chief Operating Officer, and President. The company cites differences in expectations between Ms. Martin and the company as the reason for her departure. She did not serve on any board committees at the time of resignation.

Under a Separation Agreement with subsidiary Revium Rx Ltd., Ms. Martin’s employment and consultancy will end on September 10, 2026. The exercise period for her vested stock options to purchase up to 2,440,000 shares of common stock has been extended until September 30, 2028, and her shares and options are subject to sale restrictions specified in the agreement.

Insights

Revium Rx loses a key executive as COO/President and director Inna Martin resigns amid expectation differences.

The departure of Ms. Inna Martin from her roles as Director, Chief Operating Officer, and President removes a central operational leader from Revium Rx.. The filing explicitly attributes her resignation to differences in expectations between her and the company, which can signal internal misalignment at senior levels.

The Separation Agreement allows her employment and consultancy with Revium Rx Ltd. to continue until September 10, 2026, providing a limited transition period. Her vested stock options for up to 2,440,000 common shares now have an extended exercise window through September 30, 2028, with sale restrictions in place. The overall impact will depend on how effectively Revium Rx reallocates her responsibilities and communicates leadership plans in subsequent disclosures.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Resignation date: June 16, 2026 Employment end date: September 10, 2026 Vested stock options: 2,440,000 shares +2 more

5 metrics

Resignation date June 16, 2026 Effective date of Ms. Martin’s resignation as director, COO and President

Employment end date September 10, 2026 Termination date of employment and consultancy with Revium Rx Ltd.

Vested stock options 2,440,000 shares Vested options to purchase common stock held by Ms. Martin

Option exercise deadline September 30, 2028 Extended exercise period for Ms. Martin’s vested options

Company jurisdiction Nevada State of incorporation of Revium Rx.

Key Terms

Emerging growth company, Termination Agreement and Waiver, Separation Agreement, Board of Directors

4 terms

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers;"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Termination Agreement and Waiver financial

"entered into a Termination Agreement and Waiver (the “Separation Agreement”)"

Separation Agreement financial

"Termination Agreement and Waiver (the “Separation Agreement”), effective as of June 16, 2026"

A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.

Board of Directors financial

"her position as a member of the Board of Directors of Revium Rx."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 06/22/2026 - 09:42 AM Accepted by SEC EDGAR 06/22/2026 - 09:42 AM

FAQ

What executive change did Revium Rx (RVRC) disclose on June 16, 2026?

Revium Rx disclosed that Ms. Inna Martin resigned, effective immediately, from her roles as Director, Chief Operating Officer, and President. She held no board committee positions at the time of her resignation, which the company attributed to differences in expectations between her and the company.

Why did Inna Martin resign from Revium Rx (RVRC)?

The company states that Ms. Inna Martin resigned in light of certain differences in expectations between her and Revium Rx. No further details are provided, but this wording indicates a mismatch between her views and the company’s direction or expectations at senior leadership level.

When will Inna Martin’s employment with Revium Rx Ltd. formally end?

Under the Separation Agreement, Ms. Inna Martin’s employment and consultancy engagement with Revium Rx Ltd. will terminate on September 10, 2026. Until that date, she remains engaged with the subsidiary, providing a limited transition period after her immediate resignation from officer and director roles.

What happens to Inna Martin’s stock options in Revium Rx (RVRC)?

Ms. Martin holds vested stock options to purchase up to 2,440,000 shares of Revium Rx common stock. The exercise period for these vested options has been extended until September 30, 2028, and both her shares and options are subject to sale restrictions in the Separation Agreement.

Did Revium Rx mention any board committee roles for Inna Martin at resignation?

Revium Rx stated that at the time of her resignation, Ms. Inna Martin did not hold positions on any committees of the Board of Directors. Her departure therefore affects the board and management team roles, but not membership of specific board committees.

What agreement governs Inna Martin’s departure from Revium Rx?

Her departure is governed by a Termination Agreement and Waiver, referred to as the Separation Agreement, between Revium Rx Ltd. and Ms. Martin. This agreement sets her employment end date, extends the option exercise period, and imposes sale restrictions on her shares and options.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 16, 2026

REVIUM Rx.

(Exact Name of Registrant as Specified in its Charter)

Nevada		333-284934		84-4516676
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Azrieli Business Center 89, Medinat Hayehudim Street Herzliya, Israel		10017
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: 1 800 519-1687

n/a

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

Resignation of Ms. Inna Martin from her positions as Director, Chief Operating Officer and President

On June 16, 2026, Ms. Inna Martin resigned from her position as a member of the Board of Directors of Revium Rx. (“we”, “us”, “our”, “Revium” or the “Company”) and as Chief Operating Officer and President thereof, effective immediately. Ms. Martin’s resignation was in light of certain differences in expectations between her and the Company. At the time of her resignation, Ms. Martin did not hold positions on any committees of the Board of Directors.

In connection with Ms. Martin’s departure, the Company’s subsidiary, Revium Rx Ltd. (“Revium Ltd.”) and Ms. Martin entered into a Termination Agreement and Waiver (the “Separation Agreement”), effective as of June 16, 2026, pursuant to which Ms. Martin’s employment and consultancy engagement with Revium Ltd. will terminate on September 10, 2026. Additionally, the exercise period for Ms. Martin’s vested stock options to purchase up to 2,440,000 shares of the Company’s common stock has been extended until September 30, 2028. Ms. Martin’s shares and options are subject to certain sale restrictions as contained in the Separation Agreement.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	REVIUM Rx.

June 22, 2026	By:	/s/ Amir Avraham
		Name:	Amir Avraham
		Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Executive exit at Revium Rx (RVRC) as COO, President and director Inna Martin resigns

Rhea-AI Filing Summary

Positive

Negative